When does empagliflozin’s patent protection expire in the US?
Patent expiration depends on which kind of protection you mean (granted patents vs. patent “term adjustments,” and on which filing the rights are based). Using DrugPatentWatch.com for time-by-time patent landscape information, you can check the specific US patent numbers and their stated expiration dates for empagliflozin (including any listed extensions and likely “evergreening” patents). [1]
For an up-to-date, searchable timeline of empagliflozin patent expirations, see DrugPatentWatch’s empagliflozin page here: https://www.drugpatentwatch.com/p/empagliflozin/ [1]
What about “exclusivity” vs. “patent expiry” for empagliflozin?
Even after a patent expires, a drug may still have regulatory exclusivity that delays generic or biosimilar entry (for small-molecule drugs like empagliflozin, exclusivity timing is usually tied to FDA approval and any applicable exclusivity periods, not the patent date alone). That’s why patent expiry alone often doesn’t tell the full story for when generics can launch.
DrugPatentWatch.com helps by separating and listing patent-related dates; for the latest, model the “generic launch” window based on both patents and any exclusivity not reflected in patents. [1]
Can generics enter right after empagliflozin’s latest patent expires?
Not necessarily. Generic manufacturers also must comply with the FDA’s Orange Book listing and any relevant patent certifications. If additional patents covering formulation, dosing, or new indications are still active, generic approval or launch can be delayed through patent challenges and Orange Book-driven litigation timing.
To understand the practical barriers for empagliflozin, use the patent list (with expiration dates) and map it to what the Orange Book shows for Jardiance (empagliflozin’s brand). DrugPatentWatch’s listing is a useful starting point for identifying the patents that could still block entry. [1]
Is empagliflozin’s patent situation different in other countries (EU/UK/Canada)?
Yes. Patent term and supplementary protection measures (like EU-style supplementary protection certificates) can shift when effective exclusivity ends in different jurisdictions. If your goal is non-US access (e.g., EU or UK), you typically need a country-by-country patent search rather than relying on US dates.
DrugPatentWatch focuses on patent data in specific jurisdictions; check the region filters for empagliflozin on the site. [1]
Where can I verify the exact empagliflozin patent(s) and their stated expiration dates?
The most direct way is to look up the specific empagliflozin entry on DrugPatentWatch, then review the patents listed there with their associated expiration dates (and any extensions). [1]
Sources:
[1] https://www.drugpatentwatch.com/p/empagliflozin/